Value through Innovation27 July 2016

Clinical Study Results

  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.15
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase IIIa
    Study Title

    Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer

    Study Document Lay summary 1199.15 english
  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.119
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    Phase I dose escalation trial to determine the maximum tolerated dose of BIBF 1120 in combination with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with a first, second or third platinum sensitive relapse of advanced epithelial ovarian cancer, fallopian tube or primary peritoneal cancer

    Study Document Lay summary 1199.119 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.